Bile Acid Sequestrants Market size is expected to reach USD 31 Billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of bile acid sequestrants was over USD 19 Billion. The increasing frequency of hyperlipidemia worldwide will drive the market in the anticipated period. Between 2017 and 2020, 10% of adults age 20 or older worldwide had entire hyperlipidemia cases above 240 mg/dL and about 17% had high-density lipoprotein (HDL, or “good”) cholesterol levels below 40 mg/dL. The entire frequency of hyperlipidemia was 33.8%, with the following risk values: triglyceride (TG), 12.8%; hypercholesterolemia, 16.1%; high-density lipoprotein cholesterol (cHDL), 15.0%; and low-density lipoprotein cholesterol (cLDL), 42.2%.
Another factor that is set to increase the revenue rate of the bile acid sequestrants market further is the continuous research and development in this field of bile acid sequestrants globally. For example, the Gastrointestinal Drugs Advisory Committee of the FDA on May 19, 2023, voted 12-2 that the 25-mg dose of OCA, a bile acid sequestrant does not outbalance the risks of drug-inspired liver injury notwithstanding modifications in liver damaging that were showed in the REGENERATE trial. The committee also suggested against speeding up licensing for OCA, recommending the FDA mark time to look for extra data from an ongoing phase 3 trial. Some bile acid sequestrants are also FDA-licensed for adolescents (10 to 17 years of age). Moreover, bile acid sequestrants are one of the few drugs secure for kids with allelomorphic familial hypercholesterolemia. Various research is still ongoing to understand the effect of bile acid sequestrants on other chronic diseases.
Growth Drivers
Challenges
Base Year |
2023 |
Forecast Year |
2024-2036 |
CAGR |
∼8% |
Base Year Market Size (2023) |
~USD 19 Billion |
Forecast Year Market Size (2036) |
~USD 31 Billion |
Regional Scope |
|
Type (Colestid, Colestipol, Prevalite, Questran)
The colestipol segment is anticipated to hold 35% share of the global bile acid sequestrants market by the end of 2036 and this growth will be wheeled by its extensive use in reducing bad cholesterol. Colestipol is increasingly used for the therapy of basic hypercholesterolemia. It is implemented as an adjunctive treatment to dietary improvements and exercise. Daily doses of 4 to 16 grams are related to a 12 to 24% lowering in low-density lipoprotein cholesterol (LDL-C) levels. It may also lower the risk of coronary artery disease. Colestipol is also utilized off-label to cure cholestatic pruritus and irritable bowel syndrome or bile acid diarrhea. This activity reviews the symptoms, mechanism of action, negative event profile, toxicity, dosing, pharmacodynamics, and monitoring of colestipol appropriate for interprofessional team members included in maintaining primary hypercholesterolemia and related situations.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
The hospital pharmacies segment in the bile acid sequestrants market is predicted to hold the highest share of 38 % by the end of 2036. The reason behind this segment’s huge growth is that when a patient has a massive heart attack and requires more specific care and therapy, hospital pharmacies are the primary source of drugs for those people. These pharmacies also often give a bigger selection of bile acid-sequestrant medications and give patients customized dose guidelines and advice, both of which can increase patient outcomes. The global population in 2023 is 8 billion. Of these, roughly 620 million people are living with heart and circulatory diseases across the planet and are appointed to hospital pharmacies. Each year around 60 million people around the globe encounter a heart or circulatory disease. Also, as the number of hospitals globally has escalated and hyperlipidemia is becoming more general, the exercise of purchasing drugs from hospital pharmacies has become more famous.
Our in-depth analysis of the global bile acid sequestrants market includes the following segments:
Type |
|
Application |
|
Distribution Channels |
|
North American Market Statistics
The bile acid sequestrants market in the North American region to hold the highest position in the coming years due to bile acid sequestrants' high usage to treat pruritus in liver cirrhosis patients. For instance, multiple case series and randomized controlled trials (RCTs) discovered that cholestyramine is effective in substantially limiting pruritus symptoms and serum bile acids, with 75% of patients in North America reporting indication relief. cholestyramine is used for the treatment of pruritus for its activity in reducing the “pruritogens” that gather in cholestatic forms of liver disease.
European Market Analysis
The bile acid sequestrants market is expected to extend substantially in Europe throughout the anticipated time frame. Some factors affecting the market growth involve the increasing prevalence of type 2 diabetes in the area. Diabetes is more common among older people: 19.3 million people 60-79 years old have diabetes across EU countries, in comparison with 11.3 million people 40-59 years old and only 1.7 million 20-39 years old. While more men than women have diabetes in middle age (between 40 and 59 years old), a higher number of women have diabetes after age 70 primarily because they live longer. Also, the region is experiencing a demand for potent drug treatments because of the region's substantial patient base of people with cardiovascular disorders, particularly hyperlipidemia. For market players in the region, technological developments in drug delivery methods and the creation of novel medications should present profitable growth prospects.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?